Therefore, by inhibiting the NLRP3 inflammasome in COVID-19, Nrf2 activators may significantly decrease SARS-CoV-2 infection-induced inflammation (Mendonca and Soliman 2020). Here, NFE2L2 is linked to COVID-19.